Nasdaq:US$8.59 (-1.02) | HKEX:HK$15.54 (+0.00) | AIM:£1.46 (-0.1)
Search Result
Previous Article   |   Next Article
Scientific Publications | 12 Dec 2021

ASH 2021: Preliminary Results from a Phase I Study of HMPL-523, a Selective, Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma.